Tenaya Therapeutics announced that it has received acceptance for several abstracts to be presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Boston, Massachusetts, scheduled for May 11‑15, 2026. The company’s most prominent abstract is a late‑breaking oral presentation of interim data from the RIDGE‑1 Phase 1b/2 trial of its TN‑401 gene therapy for adults with PKP2‑associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
The oral presentation is scheduled for Friday, May 15, 2026, from 8:00 am to 9:00 am EDT. It will showcase safety, biopsy, and efficacy results from both dose cohorts—3 × 10¹³ vg/kg and 6 × 10¹³ vg/kg—presented by Dr. John Giudicessi of the Mayo Clinic. The abstract title is “Interim Data from RIDGE‑1: A Phase 1b/2 Interventional Study to Evaluate Safety and Efficacy of TN‑401, an AAV9 Investigational Gene Replacement Therapy, in Adults with PKP2‑Associated Arrhythmogenic Right Ventricular Cardiomyopathy.”
In addition to the oral session, Tenaya has secured poster presentations on two other topics: a survey of parental perceptions of gene therapy for pediatric cardiomyopathy on Tuesday, May 12, 2026, and a development update on its TN‑501 gene‑editing candidate for PLN‑R14del‑associated dilated cardiomyopathy on Thursday, May 14, 2026. Both posters will be presented from 5:00 pm to 6:30 pm EDT.
The acceptance of these abstracts and the scheduled presentations represent a key milestone in Tenaya’s clinical development timeline. The oral presentation will provide the first public view of TN‑401’s safety and early efficacy profile, a critical data point that can shape the company’s regulatory strategy and attract potential partnership opportunities. The company also faces a Nasdaq compliance challenge, as its stock price has remained below $1.00 for 30 consecutive business days, with a deadline of July 27, 2026, to regain compliance. The upcoming data presentation offers a chance to strengthen investor confidence amid this regulatory hurdle.
Following the announcement, Tenaya’s stock rose 5.95% to $0.71, adding approximately $9 million to its market capitalization. The positive market reaction reflects investor enthusiasm for the first public disclosure of TN‑401 data and the potential implications for the company’s future growth and partnership prospects.
Tenaya plans to host a webcast conference call after the ASGCT meeting to discuss the TN‑401 data in detail. The company’s leadership will likely outline the implications of the interim results for regulatory submissions and potential collaborations, underscoring the strategic importance of the data presented at the conference.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.